11/15/2013 11:41:20 AM
by Richard Daverman, PhD
November 15, 2013 -- WuXi PharmaTech announced that its CMO subsidiary, Shanghai SynTheAll Pharma, will produce commercial supplies of Imbruvica, a newly approved treatment for mantle cell lymphoma developed by Pharmacyclics. WuXi has been manufacturing the drug during its clinical trials. Imbruvica was approved by the US FDA as a second-line treatment earlier this week under a Breakthrough program that OK’d the drug after it completed a Phase II clinical trial. More details....
Stock Symbol: (NYSE: WX) (NSDQ: PCYC)
Help employers find you! Check out all the jobs and post your resume.
comments powered by